January 8, 2026
In July 2025, the International Collaboration on Cosmetics Safety (ICCS) published its Best Practice Guidance (BPG) Document on Skin Sensitization Assessment , supporting the consistent and scientifically robust use of New Approach Methodologies (NAMs). The guidance has been widely welcomed by regulators and safety assessors as a critical step toward strengthening confidence in non-animal approaches for cosmetic ingredient safety evaluation. As regulatory frameworks worldwide continue to advance toward animal-free safety decisions, implementation is the decisive next step. To support this transition, ICCS is convening a free, in-depth webinar focused on how the Guidance can be applied in real-world regulatory risk assessments for skin sensitization. From guidance to practice: This session will demonstrate how defined approaches under OECD Guideline 497— including the 2 out of 3 (2o3), the Integrated Testing Strategy (ITS), and the SARA-ICE model—can be used together within practical, decision-ready risk assessment workflows. Webinar Details Thursday, April 9, 2026 1:00 – 4:30 PM CET Format: Virtual | Free to Attend Speakers and Presentations Donna Macmillan, PhD – Director, Outreach & Capacity Building, ICCS An Introduction to the ICCS Best Practice Guidance Document on Skin Sensitization Petra Kern, PhD – Senior Toxicologist/Risk Assessor, Procter & Gamble A Deep Dive into OECD GL 497 Defined Approaches: 2o3 and ITS Georgia Reynolds, MSc – Safety Science Leader, Unilever Applying OECD GL 497 Defined Approaches: SARA-ICE Nathalie Alépée, PhD – Research Toxicologist & Scientific Officer, L’Oréal The ICCS BPG on Skin Sensitization in Practice: A Case Study The webinar will provide live Q&A, offering attendees the opportunity to engage directly with the speakers and discuss practical, regulatory-relevant questions. Who Should Attend This session is designed for regulatory scientists, safety assessors, and technical experts working across regulatory agencies, industry, and associated research organizations who are involved in skin sensitization assessment and the application of NAM-based evidence. Join ICCS and leading experts to explore how NAMs can be confidently applied in regulatory practice and help support robust decision-making without the use of animals.
